Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 197

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 5
Chunk 197
---
              
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  State guaranteed loan Société Générale                  5,167                5,167      5,167                 15,502  
  State guaranteed loan BNP Paribas                       2,222                2,221      2,220                  6,662  
  Lease liabilities – Building "Le Virage"       133                 —                                 133              
  Lease liabilities – Premises Innate Inc        104                 62                                166              
  Lease liabilities – Vehicles                    32                 24                                 76              
  Lease liabilities - Printers                     9                 —                                   9              
  Loans – Equipment                               43                 —                                  43              
  Loan – Building                                         1,427                1,427      1,427                  9,510  
  Total                                                   9,137                8,901      8,829                 32,102  

Liquidity position

Cash, cash equivalents and short-term investments decreased by €11.7 million, or 13%, to €80.8 million as of December 31, 2024, as compared to cash, cash equivalents and short-term investments of €92.5 million as of December 31, 2023. Net cash as of December 31, 2024 amounted to €72.1 million (€83.5 million as of December 31, 2023). Net cash is equal to cash, cash equivalents and short-term investments less current financial liabilities. Net cash is a non-IFRS financial indicator that is reviewed by the Company’s management and that the Company believes provides useful information to investors with respect to measuring cash resources that are available for strategic investment. Net cash is not defined by IFRS and is not a substitute for “cash and cash equivalents” as reported under IFRS. The term net cash may be interpreted differently by other companies and under different circumstances. Cash and cash equivalents are mainly composed of current bank accounts, interest-bearing accounts, fixed-term accounts and money market funds as per AMF definition. Short-term investments primarily consist of shares of mutual funds and all investments with a maturity less than one year. Their purpose is to finance Innate's activities, including Innate's research and development costs.

As a reminder, Innate has received a total of €309.3 million in cash from capital increases, before deducting the costs associated